Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Kymera Therapeutics has received a consensus rating of "Buy" from twenty analysts, with an average one-year target price of $59.95.
• The company's stock recently opened at $58.50 and has demonstrated a 4.0% increase in value.
• Kymera Therapeutics reported a quarterly loss of ($0.95) EPS, which is less favorable than the consensus estimate of ($0.83), along with a significant decline in revenue compared to the previous year.

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have earned a consensus rating of "Buy" from the twenty analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $59.9474.

KYMR has been the topic of several recent research reports. Barclays began coverage on shares of Kymera Therapeutics in a research note on Wednesday, September 17th. They issued an "overweight" rating and a $60.00 price objective on the stock. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, June 25th. B. Riley upgraded shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price target on the stock in a research note on Wednesday, July 30th. Guggenheim restated a "buy" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. Finally, The Goldman Sachs Group raised Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th.

Kymera Therapeutics Stock Up 4.0%

KYMR opened at $58.50 on Tuesday. The firm has a 50 day moving average price of $44.84 and a 200-day moving average price of $38.80. The stock has a market capitalization of $4.18 billion, a price-to-earnings ratio of -16.86 and a beta of 2.17. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $58.60.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same period in the previous year, the firm earned ($0.58) EPS. The business's revenue was down 55.1% on a year-over-year basis. As a group, analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 79,220 shares of the company's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the transaction, the chief financial officer owned 227,409 shares of the company's stock, valued at approximately $11,370,450. This represents a 25.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares of the company's stock, valued at $32,363,618. The trade was a 4.34% decrease in their position. The disclosure for this sale can be found here. 16.01% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KYMR. Siren L.L.C. boosted its holdings in shares of Kymera Therapeutics by 9.1% during the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock valued at $88,687,000 after purchasing an additional 270,580 shares during the last quarter. Rhumbline Advisers boosted its holdings in Kymera Therapeutics by 9.0% during the 1st quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after acquiring an additional 5,771 shares during the period. Ameriprise Financial Inc. bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $344,000. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 3,851.5% in the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after acquiring an additional 6,509 shares in the last quarter. Finally, Hsbc Holdings PLC grew its stake in Kymera Therapeutics by 6.1% in the first quarter. Hsbc Holdings PLC now owns 18,547 shares of the company's stock worth $508,000 after purchasing an additional 1,064 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.